Abatacept (Orencia) intravenous therapy coverage
Customize your policy alerts
Sign up for mediviewcurative Policy MM-PNP-048 alerts
Get alerted when Policy MM-PNP-048 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and precertification requirements for intravenous abatacept (Orencia IV) for Curative members, including initial and continuation criteria across rheumatologic and transplant-related indications and prescriber specialty requirements.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Initial Therapy Criteria
Covered when ALL of the following are met for the listed indication groups
See TB screening and prescriber specialty requirements.
Previous biologic/targeted synthetic therapy satisfies initial pathway.
Includes disease severity and high‑risk joint qualifiers.
Age ≥2 years required.
Applies to adults and children ≥2 years.
Both donor type and combination therapy required.
Other indications are considered experimental/investigational.
Continuation Therapy Criteria
Covered when ALL of the following are met for continuation of therapy
Includes new members using the requested medication who meet initial criteria.
Evidence of positive clinical response required.
Improvement from baseline required.
Improvement from baseline required.
Continuation allowed if initial criteria continue to be met.
Continuation of Therapy
Covered when ALL of the following are met
Applies to all members including new members.
If latent TB is identified, treatment must be started before initiation of the requested medication.
Curative considers all other indications for abatacept (Orencia) to be experimental and investigational. This policy limits coverage to the specific indications and criteria listed; uses of abatacept outside those defined scenarios are not covered.
Do not administer abatacept (Orencia) to members with active tuberculosis (TB) infection. If TB screening is positive, further testing must be performed to exclude active disease; when latent TB is identified, treatment must be started prior to initiating the requested medication.
Orencia IV (intravenous abatacept) is not considered medically necessary when less costly alternative targeted immune modulators that are at least as likely to provide equivalent therapeutic results are available and the member has no documented contraindication, intolerance, or ineffective response to those alternatives. Curative requires documentation of contraindication, intolerance, or treatment failure with equivalent lower-cost agents before approving Orencia IV.
Prior Authorization, Documentation, and Prescriber Requirements
Precertification required
Precertification of intravenous abatacept (Orencia IV) is required for all Curative participating providers; obtain prior authorization before administering or billing for Orencia IV.
Continuation of therapy requirements
Continuation requests apply to all members (including new members) who meet the initial authorization criteria; if TB screening is positive, further testing to exclude active disease is required and latent TB must be treated before initiation.
Required trials of alternative targeted immune modulators
Document a contraindication, intolerance, or ineffective response to the required alternative targeted immune modulators before approving Orencia IV; for RA and PsA this includes one-month trials of Simponi Aria and Avsola or Inflectra (IV formulation) when applicable.
Step therapy not detailed
No additional step therapy requirements are specified beyond the continuation criteria and TB screening notes; follow the documented continuation and TB requirements for ongoing approval.
TB screening documentation
For patients naïve to biologic or targeted synthetic drugs, provide documentation of a negative TB test (PPD, IGRA, or chest x‑ray) within 6 months prior to initiating therapy; if TB screening is positive, additional testing to exclude active disease is required.
Prescriber specialty or documented consultation required
Prescriber must be the appropriate specialist or there must be documented consultation: rheumatologist for RA and JIA; rheumatologist or dermatologist for PsA; oncologist or hematologist for aGVHD, chronic GVHD, and ICI‑related toxicity.
Additional documentation may be requested
Curative may request additional documentation to make coverage determinations; this may include patient records, test results, and provider credentials.
Denial risk: missing precertification
Failure to obtain the required precertification for intravenous abatacept (Orencia IV) may result in denial of authorization requests.
Denial risk: alternatives not tried
Requests for Orencia IV without documentation of contraindication, intolerance, or ineffective response to the required alternative targeted immune modulators (including the one‑month trials specified for RA and PsA) may be denied.
TB screening and active infection — do not administer if active TB
Do not administer the requested medication to members with active TB infection; if TB screening is positive, additional testing must confirm no active disease prior to initiation.
Drug and Policy Background
Abatacept (Orencia) is a targeted immune modulator used for autoimmune and immune-mediated conditions including rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and certain graft-versus-host disease and immune checkpoint inhibitor–related toxicities. Curative restricts the intravenous formulation primarily to the medically necessary indications and situations described in this policy and requires documentation of prior therapies, prescriber specialty or consultation, and appropriate tuberculosis screening prior to initiation or continuation of therapy.
Definitions and Screening Notes
Policy Revision History
Policy MM-PNP-048 for intravenous abatacept (Orencia IV) became effective; precertification required for all participating providers.
Original effective date and document control information recorded for the policy (author/approvals noted in Document Control).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.